Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
Lancet (London, England) (2022) - Comments
pubmed: 34953526  doi: 10.1016/s0140-6736(21)02753-7  issn: 0140-6736  issn: 1474-547x 

Scott A Halperin, Lingyun Ye, Donna MacKinnon-Cameron, Bruce Smith, Pedro E Cahn, Guillermo M Ruiz-Palacios, Aamer Ikram, Fernando Lanas, M Lourdes Guerrero, Sergio Raúl Muñoz Navarro, Omar Sued, Dmitry A Lioznov, Vitalina Dzutseva, Ghazala Parveen, Fengcai Zhu, Laura Leppan, Joanne M Langley, Luis Barreto, Jinbo Gou, Tao Zhu